AITeQ:一种用于预测阿尔茨海默病的机器学习框架,使用独特的五基因特征
Ishtiaque Ahammad1, Anika Bushra Lamisa1, Arittra Bhattacharjee1
1Bioinformatics Division, National Institute of Biotechnology, Ganakbari, Ashulia, Savar, Dhaka 1349, Bangladesh.
Briefings in bioinformatics
|June 15, 2024
概括
本研究介绍了AITeQ,这是一种利用机器学习和RNA测序数据识别阿尔茨海默病的新型工具. 它确定了早期检测的关键基因,改善了这种神经退行性疾病的诊断能力.
科学领域:
- 基因组学就是基因组学.
- 计算生物学 计算生物学
- 神经科学是一个神经科学.
背景情况:
- 像阿尔茨海默氏症这样的神经退行性疾病对全球健康构成重大挑战.
- 复杂的病因和缺乏可靠的生物标志物阻碍了早期诊断.
- RNA测序 (RNA-seq) 为生物标志物发现提供了潜力.
研究的目的:
- 开发一种机器学习 (ML) 模型,使用RNA-seq数据识别阿尔茨海默病.
- 创建一个可访问的工具,阿尔茨海默氏症识别工具 (AITeQ),用于诊断支持.
- 为了确定一组最少的基因,表明阿尔茨海默病.
主要方法:
- 分析RNA-seq数据以确定差异表达的基因.
- 应用ML协议,包括特征选择,模型训练和超参数调整.
- 使用优化的集体ML模型 (逻辑回归,天真贝叶斯,支持向量机器) 开发AITeQ.
主要成果:
- 从RNA-seq数据中鉴定出87个差异表达的基因.
- 通过特征选择将基因组减少到五个关键基因 (CNKSR1,EPHA2,CLSPN,OLFML3,TARBP1).
- 开发了AITeQ,一个集体ML模型,在识别阿尔茨海默病方面表现出高性能.
结论:
- AITeQ提供了一种新的,数据驱动的方法来识别阿尔茨海默病.
- 鉴定的基因组和ML模型对早期诊断应用有很大的前景.
- AITeQ工具是公开可用的,用于进一步的研究和开发.
更多相关视频
06:46Automated, Long-term Behavioral Assay for Cognitive Functions in Multiple Genetic Models of Alzheimer's Disease, Using IntelliCage
Published on: August 4, 2018
12.1K
12:18A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
Published on: January 11, 2020
7.5K
相关概念视频
Alzheimer's Disease: Overview
462
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
462
Alzheimer's Disease: Treatment
179
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
179
